Ken Yamamoto, Katsuya Hirano, Temiko Shimada, Akito Hata
{"title":"Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report.","authors":"Ken Yamamoto, Katsuya Hirano, Temiko Shimada, Akito Hata","doi":"10.1016/j.jtocrr.2025.100793","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.</p>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 9","pages":"100793"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356393/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jtocrr.2025.100793","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
